Search Result

Results for "

ATM Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (43) Akt (1) Amyloid-β (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (15) Autophagy (1) Bacterial (4) Beta-lactamase (1) c-Met/HGFR (1) Caspase (1) CDK (2) Checkpoint Kinase (Chk) (2) Choline Kinase (1) Cholinesterase (ChE) (1) CMV (3) DNA-PK (1) DNA/RNA Synthesis (6) Drug Derivative (1) EGFR (1) Endonuclease (1) ERK (1) Ferroptosis (1) FLAP (1) Fungal (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HSV (3) IAP (1) Isotope-Labeled Compounds (1) JNK (1) MicroRNA (1) Molecular Glues (1) mTOR (5) Myosin (3) NF-κB (1) Notch (1) Nucleoside Antimetabolite/Analog (3) p38 MAPK (1) PARP (2) PD-1/PD-L1 (2) Phosphatase (2) PI3K (2) PROTACs (1) PTEN (1) RAD51 (1) Reference Standards (4) STING (2) Topoisomerase (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (56) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (4)

By Targets:

ATM/ATR (43)

Akt (1)

Amyloid-β (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (15)

Autophagy (1)

Bacterial (4)

Beta-lactamase (1)

c-Met/HGFR (1)

Caspase (1)

CDK (2)

Checkpoint Kinase (Chk) (2)

Choline Kinase (1)

Cholinesterase (ChE) (1)

CMV (3)

DNA-PK (1)

DNA/RNA Synthesis (6)

Drug Derivative (1)

EGFR (1)

Endonuclease (1)

ERK (1)

Ferroptosis (1)

FLAP (1)

Fungal (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HSV (3)

IAP (1)

Isotope-Labeled Compounds (1)

JNK (1)

MicroRNA (1)

Molecular Glues (1)

mTOR (5)

Myosin (3)

NF-κB (1)

Notch (1)

Nucleoside Antimetabolite/Analog (3)

p38 MAPK (1)

PARP (2)

PD-1/PD-L1 (2)

Phosphatase (2)

PI3K (2)

PROTACs (1)

PTEN (1)

RAD51 (1)

Reference Standards (4)

STING (2)

Topoisomerase (1)

VEGFR (1)

γ-secretase (1)

By Research Areas:

Cancer (56)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0097

Floxuridine 10+ Cited Publications 5-Fluorouracil 2'-deoxyriboside	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-12016

KU-55933 Maximum Cited Publications 62 Publications Verification	ATM/ATR Autophagy	Cancer
KU-55933 is a potent *ATM* inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-109566

AZD1390 5+ Cited Publications	ATM/ATR	Inflammation/Immunology Cancer
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant *ATM* inhibitor with an IC₅₀ of 0.78 nM in cell .

HY-12061

KU-60019 25+ Cited Publications	ATM/ATR	Cancer
KU-60019 is an improved *ATM* kinase-specific inhibitor with IC₅₀ of 6.3 nM.

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR Inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-100016

AZD0156 10+ Cited Publications	ATM/ATR Apoptosis	Cancer
AZD0156 is a potent, selective and orally active *ATM* inhibitor with an IC₅₀ of 0.58 nM. AZD0156 inhibits the *ATM*-mediated signaling, prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis .

HY-19959

Mirin 5+ Cited Publications	ATM/ATR Apoptosis	Cancer
Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC₅₀=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-123834

FEN1-IN-1 5+ Cited Publications	FLAP ATM/ATR	Cancer
FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg ²⁺ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .

HY-162472

XRD-0394	ATM/ATR DNA-PK	Cancer
XRD-0394 is a potent and orally active dual ATM and DNA-PKcs inhibitor with IC₅₀s of 0.39 nM and 0.89 nM, respectively. XRD-0394 shows selectivity over other PIKK and PI3K family members. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .

HY-171124

Tilatamig samrotecan AZD9592	Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis	Cancer
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .

HY-15520

CGK733 5+ Cited Publications	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-16705

BRD4770 5 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-150617

Lartesertib 1 Publications Verification M4076; ATM Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase *ATM* with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-117693

(E/Z)-Mirin 5+ Cited Publications	ATM/ATR	Cancer
(E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active *ATM* inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-162002

WSD0628	ATM/ATR	Cancer
WSD0628 is a brain penetrant and potent *ATM* inhibitor with profound radiosensitizing effect .

HY-11002

CP-466722 4 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of *ATM, with an IC₅₀* of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-103241

Ro 90-7501 3 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits *ATM* phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-163944

LL-K12-18	DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP	Cancer
LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC₅₀ value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .

HY-161615

PROTAC ATR degrader-2	PROTACs ATM/ATR Apoptosis	Inflammation/Immunology Cancer
PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC₅₀ of 29.6 nM against ATR, and its IC₅₀ values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of ATR protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .

HY-160096

M3541	ATM/ATR	Cancer
M3541 is a potent, ATP-competitive and selective *ATM* inhibitor with an IC₅₀ of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities .

HY-112305

AZ32	ATM/ATR	Cancer
AZ32 is an orally bioavailable and blood-brain barrier-penetrating *ATM* inhibitor with an IC₅₀ of <6.2 nM for ATM enzyme, and an IC₅₀ of 0.31 μM for ATM in cell.

HY-100948

ATM-3507	Myosin	Cancer
ATM-3507 is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-118911

ATM Inhibitor-10	ATM/ATR	Cancer
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active *ATM* inhibitor (IC₅₀: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .

HY-170844

MU147	Endonuclease	Cancer
MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer activity, which is lethal to Ehrlich ascites tumor cells both in vitro and in vivo. MU147 also eliminates the double-strand break repair mechanism dependent on the MRE11 nuclease activity without impairing the activation of ATM. MU147 also impairs the degradation of nascent strands of stalled replication FOX and selectively affects brca2-deficient cells .

HY-B0097R

Floxuridine (Standard) 5-Fluorouracil 2'-deoxyriboside (Standard)	Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (Standard) is the analytical standard of Floxuridine. This product is intended for research and analytical applications. Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of *ATM* protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-18650

KU 59403 1 Publications Verification	ATM/ATR	Cancer
KU 59403 is a potent *ATM* inhibitor, with IC₅₀ values of 3 nM, 9.1 μM and 10 μM for ATM, DNA-PK and PI3K, respectively .

HY-19731

SID 3712249 MiR-544 Inhibitor 1	MicroRNA Apoptosis	Cancer
SID 3712249 (MiR-544 Inhibitor 1) is a miR-544 biogenesis inhibitor. SID 3712249 binds directly to the precursor miRNA. SID 3712249 blocks production of the mature microRNA and decreases miR-544, HIF-1α, and ATM transcripts. SID 3712249 can be used in the research of cancers, such as breast cancer .

HY-112614

ATM Inhibitor-1	ATM/ATR	Cancer
ATM Inhibitor-1 is a highly potent, selective and orally active *ATM* inhibitor, with an IC₅₀ of 0.7 nM, shows weak activity against mTOR (IC₅₀, 21 μM), DNAPK (IC₅₀, 2.8 μM), PI3Kα (IC₅₀, 3.8 μM), PI3Kβ (IC₅₀, 10.3 μM), PI3Kγ (IC₅₀, 3 μM) and PI3Kδ (IC₅₀, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity .

HY-N6576

Hellebrigenin	p38 MAPK ERK JNK IAP PARP Apoptosis Caspase	Cancer
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the *ATM* pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .

HY-162002A

(S)-WSD0628	ATM/ATR	Cancer
(S)-WSD0628 (Compound 28) is the S-isomer of WSD0628 (HY-162002). (S)-WSD0628 is the inhibitor for *ATM* that inhibits the phosphorylation of ATM in MCF-7 cell with IC₅₀ <100 nM. (S)-WSD0628 exhibits radiosensitizing activity. (S)-WSD0628 can cross blood-brain barrier .

HY-150617A

(Rac)-Lartesertib (Rac)-M4076; (Rac)-ATM Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
(Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase *ATM* with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-155090

ATM Inhibitor-8	ATM/ATR	Cancer
ATM Inhibitor-8 (Compound 10r) is a highly potent, selective and orally active *ATM* inhibitor,with an IC₅₀ of 1.15 nM. ATM Inhibitor-8 exhibits anti-tumor activity .

HY-174989

ATM-IN-2	ATM/ATR Apoptosis	Cancer
ATM-IN-2 is a selective and orally active *ATM* inhibitor with an IC₅₀ of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .

HY-142931

ATM-IN-1	ATM/ATR	Neurological Disease Cancer
ATM-IN-1 is a potent inhibitor of *ATM. ATM* is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3) .

HY-100948B

ATM-3507 trihydrochloride	Myosin	Cancer
ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-155091

ATM Inhibitor-9	ATM/ATR	Cancer
ATM Inhibitor-9 (Compd 7a) is a potent *ATM* inhibitor with IC₅₀5 nM for ATM kinase, useful in cancer research .

HY-153787

ATM Inhibitor-6	ATM/ATR	Cancer
ATM inhibitor-6 (A-193) is a selective *ATM* kinase inhibitor. ATM inhibitor-6 can be used in cancer research .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-144686

ATM Inhibitor-3	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-3 (compound 34) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .

HY-169310

ATM Inhibitor-11	ATM/ATR	Cancer
ATM Inhibitor-11 (Compound 1) is an inhibitor for *ATM* with an IC₅₀ of 0.32 nM. ATM Inhibitor-11 inhibits the KAP1 phosphorylation with an IC₅₀ of 0.97 nM. ATM Inhibitor-11 exhibits high exposure in the brain, heart and plasma of ICR mouse. ATM Inhibitor-11 exhibits anti-tumor efficacy in NCI-H441 xenograft mouse model .

HY-144685

ATM Inhibitor-2	ATM/ATR	Cancer
ATM Inhibitor-2 (compound 7) is a potent and selective *ATM* inhibitor, with an IC₅₀ of <1 nM .

HY-149291

ATM Inhibitor-7	ATM/ATR Apoptosis	Cancer
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC₅₀ value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .

HY-112477

Chk2-IN-1 Hymenialdisine analogue-1	Checkpoint Kinase (Chk) Choline Kinase	Cancer
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC₅₀s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .

HY-W766548

Floxuridine-13C,15N2 5-Fluorouracil 2'-deoxyriboside-¹³C,¹⁵N₂	Isotope-Labeled Compounds Apoptosis Nucleoside Antimetabolite/Analog CMV HSV Bacterial DNA/RNA Synthesis	Cancer
Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-118911A

ATM-IN-12	ATM/ATR	Cancer
ATM-IN-12 (example 1.1) is an ATM kinase inhibitor with an IC₅₀ of 1.26 μM. ATM-IN-12 can be used for the study of ATM kinase mediated disease, including cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11709

Theasaponin E1	Triterpenes Structural Classification Terpenoids Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of *ATM* protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-N6576

Hellebrigenin	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	p38 MAPK ERK JNK IAP PARP Apoptosis Caspase
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the *ATM* pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .

Cat. No.	Product Name	Chemical Structure

HY-W766548

Floxuridine-13C,15N2

Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks